This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Implied Volatility Surging for Tandem Diabetes (TNDM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Tandem Diabetes (TNDM) stock based on the movements in the options market lately.
Why Is Tandem Diabetes (TNDM) Down 9.4% Since Last Earnings Report?
by Zacks Equity Research
Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DexCom Amends Deal With Verily to Launch Advanced CGM by 2020
by Zacks Equity Research
DexCom (DXCM) and Verily to collaborate on the development of additional products and software based on DexCom's profile in the future.
Tandem Diabetes (TNDM) Reports Loss in Q3, Revenues Beat
by Zacks Equity Research
Impressive domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select international markets drove Tandem Diabetes' (TNDM) revenue beat in Q3.
What's in Store for Tandem Diabetes' (TNDM) Q3 Earnings?
by Zacks Equity Research
Strong domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets likely to drive Tandem Diabetes' (TNDM) Q3 earnings.
Tandem Diabetes (TNDM) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes (TNDM) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now
by Zacks Equity Research
Strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select international markets bode well for Tandem Diabetes (TNDM).
Implied Volatility Surging for Tandem Diabetes Care (TNDM) Stock Options
by Zacks Equity Research
Tandem Diabetes Care (TNDM) needs investors to pay close attention to the stock based on moves in the options market lately.
US Diabetes Market Gaining Momentum: 3 Stocks in Focus
by Sreyoshi Mukherjee
A rising geriatric population and lifestyle disorders are expanding the U.S. diabetic population.
Is Tandem Diabetes Care (TNDM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (TNDM) Outperforming Other Medical Stocks This Year?
Tandem Diabetes Care (TNDM) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
Tandem Diabetes Care (TNDM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Options Traders Expect Huge Moves in Tandem Diabetes Care (TNDM) Stock
by Zacks Equity Research
Tandem Diabetes Care (TNDM) needs investors to pay close attention to the stock based on moves in the options market lately.
5 Health Care ETFs Outperforming XLV on YTD Basis
by Zacks Equity Research
Health care ETFs provide handsome returns year to date.
Is the Options Market Predicting a Spike in Tandem Diabetes (TNDM) Stock?
by Zacks Equity Research
Investors need to pay close attention Tandem Diabetes (TNDM) stock based on the movements in the options market lately.
Company News For Jun 25, 2018
by Zacks Equity Research
Companies In The News are: RHT,BB,KMX,TNDM
Options Traders Expect Huge Moves in Tandem Diabetes Care (TNDM) Stock
by Zacks Equity Research
Investors in Tandem Diabetes Care (TNDM) need to pay close attention to the stock based on moves in the options market lately.
Tandem Diabetes Care (TNDM): Moving Average Crossover Alert
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson
Wall Street Brushes Off Trade War Fears: Top 5 Gainers
by Tirthankar Chakraborty
The Dow climbed more than 700 points after investors downplayed fears over tariffs announced by both China and the United States.
Tandem Diabetes Care (TNDM) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Tandem Diabetes Care, Inc. (TNDM)
New Year to Bring Back MedTech Tax, 3 Stocks Unfazed
by Zacks Equity Research
Investors are apprehensive about the re-enactment of MedTech Tax and related concerns, despite raking in returns from other sectors.
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT
by Zacks Equity Research
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT
5 MedTech Stocks for Stellar Returns in Q3
by Zacks Equity Research
Here we take a sneak peek into two burning issues that are likely to impact the quarterly numbers in the MedTech fraternity.
4 Top Growth Picks as MedTech Battle Rages On
by Zacks Equity Research
Trump's Obamacare replacement saga has made growth picks great opportunities for investors in MedTech sector.